Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126926101 | 12692610 | 1 | I | 20160817 | 20160829 | 20160829 | EXP | US-BAUSCH-BL-2016-020292 | BAUSCH AND LOMB | CHAM A, CHAM A, BANSAL M, BANDA H, BASSUK A, KWON Y, TLUCEK P, TSANG S, TSANG S, SOBOL W, FOLK J, YEH S, MAHAJAN V, MAHAJAN V. SECONDARY GLAUCOMA IN CAPN5-ASSOCIATED NEOVASCULAR INFLAMMATORY VITREORETINOPATHY. CLINICAL OPHTHALMOLOGY. 2016 JUN 27;10:1187-1197. | 24.00 | YR | M | Y | 0.00000 | 20160829 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126926101 | 12692610 | 1 | PS | DORZOLAMIDE AND TIMOLOL | DORZOLAMIDETIMOLOL | 1 | Unknown | U | 90037 | ||||||||||
| 126926101 | 12692610 | 2 | SS | DORZOLAMIDE AND TIMOLOL | DORZOLAMIDETIMOLOL | 1 | U | 90037 | |||||||||||
| 126926101 | 12692610 | 3 | SS | BRIMONIDINE | BRIMONIDINE TARTRATE | 1 | Unknown | U | 76260 | ||||||||||
| 126926101 | 12692610 | 4 | SS | BRIMONIDINE | BRIMONIDINE TARTRATE | 1 | U | 76260 | |||||||||||
| 126926101 | 12692610 | 5 | SS | LATANOPROST. | LATANOPROST | 1 | Unknown | U | 201006 | ||||||||||
| 126926101 | 12692610 | 6 | SS | LATANOPROST. | LATANOPROST | 1 | U | 201006 | |||||||||||
| 126926101 | 12692610 | 7 | SS | FLUOCINOLONE ACETATE | FLUOCINOLONE ACETONIDE | 1 | Unknown | U | 21737 | IMPLANT | |||||||||
| 126926101 | 12692610 | 8 | SS | FLUOCINOLONE ACETATE | FLUOCINOLONE ACETONIDE | 1 | U | 21737 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126926101 | 12692610 | 1 | Autoimmune retinopathy |
| 126926101 | 12692610 | 2 | Glaucoma |
| 126926101 | 12692610 | 3 | Autoimmune retinopathy |
| 126926101 | 12692610 | 4 | Glaucoma |
| 126926101 | 12692610 | 5 | Autoimmune retinopathy |
| 126926101 | 12692610 | 6 | Glaucoma |
| 126926101 | 12692610 | 7 | Autoimmune retinopathy |
| 126926101 | 12692610 | 8 | Glaucoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126926101 | 12692610 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126926101 | 12692610 | Drug effect incomplete | |
| 126926101 | 12692610 | Fibrosis | |
| 126926101 | 12692610 | Intraocular pressure decreased | |
| 126926101 | 12692610 | Retinal degeneration | |
| 126926101 | 12692610 | Visual acuity reduced |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |